Alpha thalassemia in pregnancy is an inherited blood disorder in which reduced or absent alpha-globin production causes mild to severe anemia, and its risk to mother and fetus depends almost entirely on which of the four alpha-globin genes are deleted or mutated. Carriers of one or two affected genes usually have mild microcytic anemia and generally do well with routine monitoring. Carriers of three affected genes (Hb H disease) often need transfusions during pregnancy. A fetus with all four genes affected (Hb Bart's hydrops fetalis) usually dies before or shortly after birth unless treated in utero.
The Genetic Mechanism: Four Genes, Two Chromosomes
Alpha-globin is one of two protein chains that build hemoglobin, the molecule that carries oxygen. The alpha-globin cluster sits on chromosome 16, and every person inherits two copies of that cluster, one from each parent. Each copy normally carries two functional alpha-globin genes, for a total of four.
When alpha-globin output falls, the body cannot assemble enough normal hemoglobin. The unused chains that remain, particularly beta chains in adults, clump into unstable tetramers. These damaged red cells are removed early by the spleen, which produces the hemolytic anemia characteristic of the more severe forms.
The severity tracks the number of lost genes with unusual precision. One deleted gene removes roughly 25 percent of alpha-globin output. Two deleted genes (in cis on one chromosome, or in trans on both) remove about 50 percent. Three removed genes leave roughly 25 percent output and cause Hb H disease. Four removed genes leave no alpha-globin at all, and the fetus cannot make functional hemoglobin after the embryonic stage.
A non-obvious genetic detail matters for counseling: the two-gene form has two very different inheritance patterns. Deletions in cis (both genes lost on the same chromosome, common in Southeast Asian and southern Chinese populations) can pass two lost genes to a child. Deletions in trans (one gene lost on each chromosome, common in African and Mediterranean populations) cannot, because each parent passes only one affected chromosome.
In plain terms: the number of broken alpha genes, and whether they sit on one chromosome or two, determines everything about the pregnancy's risk.
Quantified Context: How Common and How Severe
Alpha thalassemia is among the most common inherited disorders worldwide. Carrier frequency for at least one deleted gene reaches 30 to 40 percent in parts of Southeast Asia and 20 to 30 percent in sub-Saharan Africa. In the United States, population screening data suggest roughly 1 in 30 African Americans and 1 in 20 Asian Americans carry a deletional form, though exact figures vary by subgroup.
The clinically important comparison is between the maternal and fetal sides of the same pregnancy. A woman with two deleted genes (alpha thalassemia trait) typically has hemoglobin around 10 to 12 g/dL, red cells that are small (MCV often 60 to 75 fL), and no anemia requiring treatment. Her main risk is not to herself but to a fetus who inherits a matching two-gene deletion from the father.
| Maternal genotype | Genes lost | Typical hemoglobin | Transfusion need in pregnancy | Key fetal risk |
|---|---|---|---|---|
| Silent carrier | 1 | 12-14 g/dL | None | None alone; matters only if partner also affected |
| Alpha thalassemia trait | 2 | 10-12 g/dL | Rare (under 5%) | 25% chance of Hb Bart's if partner carries cis deletion |
| Hb H disease | 3 | 7-10 g/dL, falls in pregnancy | 20-40% require transfusion | 25% chance of Hb Bart's if partner is a carrier |
| Hb Bart's hydrops fetalis | 4 (fetus) | Not viable without therapy | Not applicable | Usually fatal in utero or at birth |
The three-gene row is where most clinical attention focuses. Hb H disease worsens during pregnancy because plasma volume expands by 40 to 50 percent while red cell mass rises less, diluting hemoglobin. Studies of pregnant women with Hb H disease report that roughly one in four to one in three need at least one transfusion, most often in the third trimester.
For comparison, a woman with sickle cell disease faces a transfusion rate above 30 percent and a preterm birth rate near 20 to 25 percent. Hb H disease is milder but is not benign, and it is frequently under-monitored because carriers are often told their condition is "just trait."
Trimester-by-Trimester Timeline
The clinical course of alpha thalassemia in pregnancy follows a predictable arc, driven by plasma volume expansion, iron demand, and fetal hemoglobin development.
| Stage | Timing | What happens | Action |
|---|---|---|---|
| Preconception | Before conception | Partner screening; genetic counseling if both carry deletions | Determine cis vs trans pattern; offer prenatal diagnosis options |
| First trimester | Weeks 0-13 | Baseline CBC, ferritin, hemoglobin electrophoresis; confirm genotype | Establish baseline hemoglobin; start folic acid 400-1000 mcg daily |
| Second trimester | Weeks 14-27 | Plasma volume rises; hemoglobin may fall 0.5-1 g/dL | Recheck CBC at 24-28 weeks; distinguish dilution from true anemia |
| Third trimester | Weeks 28-40 | Peak dilution; highest transfusion risk in Hb H disease | Transfuse for symptomatic anemia or hemoglobin under 7 g/dL |
| Delivery | Around week 37-40 | Deliver at a center with blood bank capacity if Hb H disease | Avoid unnecessary operative delivery; prepare cross-matched blood |
| Postpartum | First 6 weeks | Hemoglobin re-equilibrates as plasma volume contracts | Recheck CBC; screen newborn with hemoglobin electrophoresis |
The timeline has one counterintuitive feature: hemoglobin often looks worst around 28 to 32 weeks, but this nadir is partly hemodilution rather than true red cell loss. A hemoglobin of 9.5 g/dL at 30 weeks in a woman with trait who was 11.5 g/dL at baseline may represent normal physiology, not disease progression. Treating the number rather than the patient leads to unnecessary transfusion.
Variations and Edge Cases
The genotype is not the whole story. Coexisting iron deficiency is common in pregnancy and can push a woman with trait into symptomatic anemia. Iron studies should be checked before assuming the anemia is purely thalassemic, because trait does not protect against iron deficiency and the two frequently coexist.
Hemoglobin Constant Spring and other non-deletional mutations produce more severe Hb H disease than pure deletions, with lower baseline hemoglobin and higher transfusion rates. A woman with compound Hb H/Constant Spring may need transfusion in the second trimester rather than the third.
Concurrent beta thalassemia trait can mask the picture. A person with one alpha and one beta deletion may have a near-normal MCV, which defeats screening algorithms that rely on mean corpuscular volume alone. This is a corrected misconception worth stating plainly: a normal MCV does not rule out alpha thalassemia when beta trait is also present.
Hydrops fetalis is now sometimes treatable. Intrauterine transfusion has allowed a small number of fetuses with four-gene deletion to survive to delivery, though long-term outcomes remain under study and the procedure is offered only at specialized centers. This is established but limited evidence, not a standard of care.
Common Misconceptions, Corrected
Alpha thalassemia trait is often described as harmless, and for the mother it usually is. The harm sits in the reproductive risk, not the carrier's own health. This is why partner testing matters more than maternal treatment.
A second misconception: low MCV always means iron deficiency. In populations where alpha thalassemia is common, microcytosis with a normal ferritin points strongly toward thalassemia, and iron supplementation will not raise the MCV.
A third: the condition worsens permanently with each pregnancy. Hemoglobin recovers after delivery as plasma volume normalizes, and there is no evidence that repeated pregnancies accelerate the underlying disorder in trait carriers.
A professional caveat: hemoglobin electrophoresis is normal in silent carriers and in some trait carriers, so a normal electrophoresis result does not exclude alpha thalassemia. Genetic testing is required to confirm the genotype.
Practical Actions and Red Flags
What to actually do depends on genotype and partner status.
- Both partners carry a two-gene cis deletion: offer prenatal diagnosis via chorionic villus sampling at 10 to 13 weeks or amniocentesis at 15 to 20 weeks.
- Mother has Hb H disease: establish care with a hematologist, check CBC every 4 to 6 weeks after 20 weeks, and deliver where blood products are available.
- Mother has trait with a partner of unknown status: order partner hemoglobin electrophoresis and, if indicated, alpha-globin genotyping before conception when possible.
- Any pregnant woman with alpha thalassemia: check ferritin, because iron deficiency is common and treatable.
- All carriers: take folic acid 400 to 1000 mcg daily, as increased red cell turnover raises folate demand.
Seek urgent evaluation for these red flags:
- Hemoglobin below 7 g/dL at any point in pregnancy.
- Shortness of breath at rest or with minimal exertion.
- Chest pain, palpitations, or fainting.
- New jaundice or dark urine suggesting hemolysis.
- Fetal growth restriction or signs of hydrops on ultrasound (fluid around the heart, lungs, or skin).
- Decreased fetal movement after 28 weeks.
Limitations of Current Evidence
The evidence base for managing alpha thalassemia in pregnancy rests largely on case series and regional cohort studies rather than randomized trials. Transfusion thresholds during pregnancy are extrapolated from sickle cell and general obstetric guidance, not from alpha thalassemia-specific data.
Outcome data for intrauterine transfusion in Hb Bart's hydrops fetalis come from small case reports, and long-term neurodevelopmental outcomes are not well characterized. Screening programs vary widely by country, and many carriers in low-resource settings are never identified before pregnancy.
The numbers cited here reflect current practice patterns and may shift as genetic testing becomes more accessible. What will not change is the core principle: the risk in alpha thalassemia in pregnancy is determined by the genotype of both parents, and the mother's own health is usually the smaller part of the story.